UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – May 12, 2022
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: 610 -594-2900
Not Applicable | ||
(Former name or address, if changed since last report.) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 12, 2022, West Pharmaceutical Services, Inc. (the “Company” or "West") announced the appointment of Bernard J. Birkett, Chief Financial Officer, to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead the Company's Global Operations and Global Supply Chain. After six years of dedicated service, the Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo, has announced his resignation to pursue other interests, with a departure date of July 2022.
The Company has also announced other leadership changes and additions, including the appointment of Cindy Reiss-Clark as the Chief Commercial Officer, which are described in further detail in the Company's press release.
Item 7.01 Regulation FD Disclosure.
On May 12, 2022, the Company issued a press release announcing the executive leadership appointments. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibit No. | Description | ||||||
99.1 | ||||||||
104 | The cover page from the Company’s Current Report on Form 8-K, dated May 12, 2022, formatted in Inline XBRL. | |||||||
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC. | |||||
/s/ Kimberly Banks MacKay | |||||
| Kimberly Banks MacKay | |||||
Senior Vice President, General Counsel and Corporate Secretary | |||||
May 12, 2022 | |||||
3
EXHIBIT INDEX
Exhibit No. | Description | |||||||
99.1 | ||||||||
104 | The cover page from the Company’s Current Report on Form 8-K, dated May 12, 2022, formatted in Inline XBRL. | |||||||
4
